PCOS Affects Up to 1 in 5 Indian Women. Here's What the Research Says About Inositol.
PCOS prevalence in India ranges from 7.2% to 19.6% depending on diagnostic criteria used, among the highest reported globally. Indian women with PCOS show insulin resistance at rates of 50 to 80%, higher than many other studied populations. Awareness of the condition is rising. Understanding of evidence based supplementation is not keeping pace.
A Condition Affecting Up To 1 In 5 Indian Women
PCOS (now also referred to as PMOS) is not a niche diagnosis. A large multicenter Indian study spanning nearly 10,000 women aged 18 to 40 found prevalence ranging from 7.2% using NIH criteria to 19.6% using Rotterdam criteria, with rates consistently higher in urban areas than rural ones. Among women with PCOS in that study, 91.9% showed dyslipidemia and 43.2% were classified as obese using Asian cutoffs.
The metabolic picture is the part that gets the least attention. PCOS is not only a reproductive condition. It is, for a majority of those affected, an insulin resistance condition with reproductive symptoms attached.
Insulin Resistance Is the Mechanism, Not Just a Side Effect
Insulin resistance has been reported in more than 60% of women with PCOS, including both obese and non-obese individuals. This matters because of the chain reaction it sets off. When cells respond poorly to insulin, the body compensates by producing more of it. Elevated insulin then stimulates the ovaries to produce excess androgens, which disrupts ovulation and drives the irregular cycles, acne, and hirsutism associated with PCOS.
This is why insulin sensitisation, not just hormone regulation, sits at the center of evidence based PCOS management. It is also where inositol enters the research.
What Myo-Inositol and D-Chiro-Inositol Actually Do
Myo-inositol and D-chiro-inositol are naturally occurring compounds, part of the vitamin B family, that act as secondary messengers in insulin signalling. In simple terms, they help cells respond to insulin more efficiently, which is the exact pathway disrupted in PCOS-related insulin resistance.
The two forms are not interchangeable, and this is the detail most consumer-facing content skips. The body maintains its own natural ratio of these two compounds at approximately 40:1, myo-inositol to D-chiro-inositol, in healthy ovarian tissue. Research has found that this specific ratio, rather than D-chiro-inositol alone or in excess, is what supports healthy ovarian function. High doses of D-chiro-inositol relative to myo-inositol have actually been associated with reduced oocyte quality in clinical studies, which is why formulation ratio matters as much as formulation presence.
Clinical research on the 40:1 ratio has measured outcomes including improved insulin sensitivity, more regular ovulation, and favourable shifts in androgen markers in women with PCOS.
AKYA's Myo-Inositol & D-Chiro-Inositol
AKYA's Myo-Inositol & D-Chiro Inositol formula is built around this exact 40:1 ratio: 2000mg of myo-inositol paired with 50mg of D-chiro-inositol. Three supporting ingredients are included for specific, evidence-linked reasons rather than as filler.
Folic acid is dosed at 129mcg, covering 99.68% of RDA, since folate is studied alongside inositol for its role in ovulation and egg quality. Chromium picolinate is included at 40mcg, covering 80% of RDA, given chromium's established role in glucose metabolism and insulin signaling. Black pepper extract at 2.5mg is included for absorption, since piperine has been shown to improve the bioavailability of coadministered nutrients.
Every ingredient and every dose is disclosed on the label. No proprietary blends, no combined weights hiding individual amounts.
What the Research Does Not Claim
This is worth stating plainly, because the supplement category in India has a documented over claiming problem. Inositol is not a cure for PCOS. It does not reverse the condition. The clinical literature describes it as supporting insulin sensitivity, ovarian function, and cycle regularity, language that reflects what the research has actually measured, not language designed to promise an outcome.
PCOS management remains multifactorial, involving diet, movement, and where needed, clinical care. Inositol supplementation, when dosed in the studied ratio, is one evidence-backed input within that broader picture, not a replacement for it.
The Takeaway
PCOS affects a significant share of Indian women, and insulin resistance underlies most of those cases. The research on inositol is specific about what works: the 40:1 myo-inositol to D-chiro-inositol ratio, not arbitrary inositol dosing. Anyone evaluating an inositol supplement should be checking for that ratio and full label disclosure before anything else.